USPTO serial 79323387
LEMONEX
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Apr 23, 2024
- Examiner
- MASON, JARED MICHAEL
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with LEMONEX?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Jong Park
Jong Park The PL Law Group, PLLC13800 Coppermine Rd, FL 1-3Herndon, VA 20171UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 035 | Wholesale store services featuring diagnostic apparatus for medical use; sales agency services, namely, retail services by direct solicitation by sales agents featuring diagnostic apparatus for medical use; wholesale store services featuring diagnostic preparations for medical or veterinary purposes; wholesale store services featuring reagents for medical use; wholesale store services featuring cosmetics; wholesale store services featuring diagnostic reagents for pharmaceutical purposes; wholesale store services featuring synthetic peptides for pharmaceutical purposes; sales agency services, namely, retail services by direct solicitation by sales agents featuring for pharmaceuticals; wholesale store services featuring pharmaceutical preparations for diagnosis; sales agency services, namely, retail services by direct solicitation by sales agents featuring for medical apparatus and instruments; sales agency services, namely, retail services by direct solicitation by sales agents featuring for medicated mouth care and treatment preparations; sales agency services, namely, retail services by direct solicitation by sales agents featuring for masks for medical purposes; wholesale store services featuring chemical reagents for medical or veterinary purposes; wholesale store services featuring biological preparations for medical purposes; sales agency services, namely, retail services by direct solicitation by sales agents featuring for testing apparatus for medical purposes; sales agency services, namely, retail services by direct solicitation by sales agents featuring for balms, other than for medical purposes; sales agency services, namely, retail services by direct solicitation by sales agents featuring for non-medicated mouthwashes; sales agency services, namely, retail services by direct solicitation by sales agents featuring for aerosol dispensers, not for medical purposes | ACTIVE | — |
| 040 | Processing of chemical reagents; processing of pharmaceutical preparations; preservation of pharmaceuticals; custom manufacture of medical devices for others; custom manufacture of biopharmaceuticals; processing of biopharmaceutical materials for others; treatment of biopharmaceutical materials; custom manufacture of pharmaceuticals; processing of medicinal materials; processing of foodstuffs for use in manufacture | ACTIVE | — |
| 042 | Scientific research and development of amino acid for medical purpose; scientific research and development of peptide for medical purposes; scientific research for medical purposes; scientific development of cell therapy products; clinical studies of medicines, namely, scientific research in the nature of conducting clinical trials of medicines for others; medical research; drug discovery services; pharmaceutical research and development; research and development of vaccines and medicines; development of pharmaceutical preparations and medicines; scientific cosmetics development services; DNA screening for scientific research purposes; research relating to biotechnology; biotechnology consulting services; scientific research and development of chemical amino acids; scientific research and development of DNA chips; scientific development of biologics; character design, namely, animation design for others | ACTIVE | — |
| 044 | Preparation and dispensing of medications; provision of dietary food supplements for medical purposes being dispensing of medications; providing medical supplements for medical purposes being dispensing of medications; providing nutritional supplements for medical purposes being dispensing of medications; providing vitamin for medical purposes being dispensing of medications; medical and health services relating to DNA, genetics and genetic testing, namely, DNA and genetic testing for medical purposes; medical analysis for the diagnosis and treatment of persons; laboratory analysis services relating to the treatment of persons, namely, medical analysis services for diagnostic and treatment purposes provided by medical laboratories; medical services relating to the removal, treatment and processing of human blood, umbilical cord blood, human cells, stem cells and bone marrow; medical analysis services for cancer diagnosis and prognosis; medical analysis services for the diagnosis of cancer; medical services in the field of oncology; medical services relating to the removal, treatment and processing of stem cells; medical testing services relating to the diagnosis and treatment of disease; medical care and analysis services relating to patient treatment; medical screening; medical services relating to the removal, treatment and processing of human cells; analysis of human tissues for medical treatment; analysis of human serum for medical treatment; provision of gene therapy for medical treatment purposes; provision of genetic information for medical treatment purposes; provision of genetic testing for medical treatment purposes; genetic testing of animals for diagnostic or treatment purposes | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by WON, Cheol Hee
- Other trademarks owned by WON, Cheol Hee
- Other trademarks owned by WON, Cheol Hee
- Other trademarks in Class 035
- Other trademarks in Class 040
- Other trademarks in Class 042
- Other trademarks in Class 044
- Similar marks named LEMONEX
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Dec 7, 2024 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Oct 22, 2024 | XXSS | GENERIC MADRID TRANSACTION SENT TO IB | — |
| Oct 21, 2024 | XXCR | GENERIC MADRID TRANSACTION CREATED | — |
| Jul 24, 2024 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Apr 23, 2024 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Apr 23, 2024 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Feb 6, 2024 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Feb 6, 2024 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Feb 5, 2024 | GPNX | NOTIFICATION PROCESSED BY IB | — |
| Jan 17, 2024 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Jan 17, 2024 | OP2R | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB | — |
| Jan 17, 2024 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Dec 5, 2023 | PBCR | WITHDRAWN FROM PUB - OG REVIEW QUERY | — |
| Apr 12, 2023 | OPNX | NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB | — |
| Mar 22, 2023 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Mar 22, 2023 | OPNR | NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB | — |
| Aug 9, 2022 | PBCR | WITHDRAWN FROM PUB - OG REVIEW QUERY | — |
| Jul 25, 2022 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Jul 25, 2022 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Jul 25, 2022 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Jul 25, 2022 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Jul 25, 2022 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Jul 20, 2022 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jul 20, 2022 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jul 20, 2022 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jul 19, 2022 | RFNP | REFUSAL PROCESSED BY IB | — |
| Jun 24, 2022 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Jun 23, 2022 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Jun 3, 2022 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Jun 2, 2022 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| May 31, 2022 | DOCK | ASSIGNED TO EXAMINER | — |
| Oct 29, 2021 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Oct 25, 2021 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Oct 22, 2021 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |